WallStreetZenWallStreetZen

NASDAQ: LPCN
Lipocine Inc Stock

Open Broker Account
$0.42-0.01 (-2.33%)
Updated Dec 6, 2022
LPCN Price
$0.42
Fair Value Price
$0.44
Market Cap
$36.73M
52 Week Low
$0.36
52 Week High
$1.89
P/E
10.38x
P/B
0.98x
P/S
2.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.59M
Earnings
$4.10M
Gross Margin
100%
Operating Margin
25.05%
Profit Margin
24.7%
Debt to Equity
0.05
Operating Cash Flow
-$1M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LPCN Overview

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LPCN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LPCN ($0.42) is undervalued by 6.11% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LPCN ($0.42) is not significantly undervalued (6.11%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LPCN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more LPCN due diligence checks available for Premium users.

Be the first to know about important LPCN news, forecast changes, insider trades & much more!

LPCN News

Valuation

LPCN fair value

Fair Value of LPCN stock based on Discounted Cash Flow (DCF)
Price
$0.42
Fair Value
$0.44
Undervalued by
4.98%
LPCN ($0.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LPCN ($0.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

LPCN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
10.38x
Industry
13.95x
Market
21.59x
LPCN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LPCN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

LPCN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
4.87x
LPCN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LPCN's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.4M
Profit Margin
0%
LPCN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LPCN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$39.4M
Liabilities
$1.8M
Debt to equity
0.05
LPCN's short-term assets ($36.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LPCN's short-term assets ($36.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LPCN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LPCN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$613.9k
Financing
$44.0
LPCN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LPCN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
LPCN$36.73M-3.94%10.38x0.98x
AVRO$36.77M-5.51%-0.34x0.37x
MBRX$36.93M-2.27%-1.48x0.63x
CLVS$36.53M-13.40%-0.14x-0.09x
MDNA$36.21M-9.57%-3.10x1.46x

Lipocine Stock FAQ

What is Lipocine's quote symbol?

NASDAQ: LPCN) Lipocine trades on the NASDAQ under the ticker symbol LPCN. Lipocine stock quotes can also be displayed as NASDAQ: LPCN.

If you're new to stock investing, here's how to buy Lipocine stock.

What is the 52 week high and low for Lipocine (NASDAQ: LPCN)?

(NASDAQ: LPCN) Lipocine's 52-week high was $1.89, and its 52-week low was $0.36. It is currently -78.04% from its 52-week high and 15.28% from its 52-week low.

How much is Lipocine stock worth today?

(NASDAQ: LPCN) Lipocine currently has 88,510,791 outstanding shares. With Lipocine stock trading at $0.42 per share, the total value of Lipocine stock (market capitalization) is $36.73M.

Lipocine stock was originally listed at a price of $10.00 in Oct 22, 2013. If you had invested in Lipocine stock at $10.00, your return over the last 9 years would have been -95.85%, for an annualized return of -29.78% (not including any dividends or dividend reinvestments).

How much is Lipocine's stock price per share?

(NASDAQ: LPCN) Lipocine stock price per share is $0.42 today (as of Dec 6, 2022).

What is Lipocine's Market Cap?

(NASDAQ: LPCN) Lipocine's market cap is $36.73M, as of Dec 7, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lipocine's market cap is calculated by multiplying LPCN's current stock price of $0.42 by LPCN's total outstanding shares of 88,510,791.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.